Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.50 |
| ▸ | BACE1 | P56817 | 12/20 | 0.49 |
| ▸ | CTSD | P07339 | 4/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601966 | 1.00 | BCHE (0.50) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL1602585 | 0.94 | BCHE (0.48) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL1602579 | 0.94 | BCHE (0.48) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL12709586 | 0.90 | KLK5 (0.48) | BCHEBACE1CTSDBACE2 | |
| SCHEMBL12709598 | 0.85 | KLK5 (0.47) | BCHEBACE1CTSDBACE2 | |
| SCHEMBL1601890 | 0.83 | BCHE (0.43) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL1601889 | 0.83 | BCHE (0.43) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL1602519 | 0.82 | BCHE (0.42) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL5104134 | 0.82 | BCHE (0.42) | BCHEBACE1CTSDBACE2SLC6A11 | |
| SCHEMBL1602517 | 0.82 | BCHE (0.42) | BCHEBACE1CTSDBACE2SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1637518-A2 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040127488-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-01 | — | — | US | disclosed |
| US-6617350-B2 | Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-09 | — | — | US | disclosed |
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
| US-6319946-B1 | BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | BCHE 949/4885BACE1 66/4885CTSD 92/4885 |
| US-20040127488-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | BCHE 949/4885BACE1 66/4885CTSD 92/4885 |
| US-20020198388-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | BCHE 949/4885BACE1 66/4885CTSD 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.